oncology where there's a wrong answer; that's a wrong answer. No chemo for relapse deletion 17p patients --fuels the fire, doesn't do the patient any good, suppresses their immune system further, and they'll land in clinic with Mollie and me, which is not so bad.
So, what happened to our patient? He started idelalisib and rituximab. We were reluctant because he had a catheter in his side to drain the pleural effusions and was also on therapeutic anticoagulation long term to give him ibrutinib for concern about bleeding risk. So he started on idelalisib and rituximab and has remained on the drug. He's very memorable because he's one of the first patients to be treated in our new hospital that opened in December of 2014. He had diarrhea, one episode that started pretty soon after he began treatment, but it resolved. He had been put on metformin in addition to his insulin, and it was probably related to that.
But we did have this other patient, and this was a patient who was treated on a clinical study with idelalisib and rituximab; he was also 82. And he did beautifully until he developed a sinus infection --as Mollie tells you it's pretty common --and he was started on Augmentin by his primary care physician, developed diarrhea, which could have been related to Augmentin, and then when it didn't resolve off the Augmentin, he was treated with two serial courses of metronidazole for Clostridium difficile diarrhea. The only problem was both tests that he had for C. diff were negative. The problem that he had when he came to see us was a pretty severe kind of diarrhea that can occur in patients taking idelalisib and it's an inflammatory colitis, late occurring. Mollie mentioned obinutuzumab; it is different in terms of its biological
behavior. It appears to be more potent than the other anti-CD20 antibodies, and it also has a very different profile for infusion reactions. Infusion reactions are most common with the first infusion, and they're usually a one and done. Many patients never experience another infusion reaction, but all patients should receive prophylaxis with antihistamines, Tylenol, as well as steroids, before the first reaction.
The first dose of obinutuzumab is broken up, it's given 100 and 900 mg to comprise the total 1 gm dose over 2 days and that has also limited the risk for infusion reactions. Neutropenia, thrombocytopenia, more common than with some of the other anti-CD20 antibodies, but haven't been associated with increased risk for infection, but does require some monitoring and should be considered when you're following these patients. If you haven't, usually check blood cell counts in patients who are coming in for subsequent weeks of rituximab, it's reasonable to do so with obinutuzumab.
Venetoclax --we spoke about the toxicities here, an increased risk for neutropenia that requires monitoring, careful administration of G-CSF in cases where their neutrophil count is severely suppressed, but does not usually require interruption of therapy. Tumor lysis is the most significant, most life-threatening risk, and really requires careful adherence to the prescribing information after CT
JADPRO LIVE at APSHO 2016 26
evaluation for lymph node bulk and careful assessment of their tumor lysis risk, per the U.S. prescribing information.
Where are we now in CLL? I met Mollie Moran 10 years ago, and we've been in practice together since that time and our world has completely changed. MOLLIE On many levels.
DR. JONES On many levels. Chemotherapy is a small part of our business now. We still see a lot of lymphoma patients, but our CLL patients are very rarely treated with chemotherapy and in fact, our whole program continues to grow as a place where patients come to avoid chemotherapy treatment for CLL. B-cell receptor signaling agents are the core of that. They are still probably the single most effective drugs in terms of the rates of response, the durability of response, and the favorable risk benefit balance, but they do require long-term therapy. And I tell patients all the time, "The absence of severe side effects is not the absence of chronic, low-level side effects." And so managing these patients over the longer term really does require attention to low-grade, niggling side effects that can adversely affect quality of life over time.
There's a lot still to come. There's a better ibrutinib maybe in the form of acalabrutinib. Venetoclax is now a part of the armamentarium, and we're trying to understand how to sequence these drugs. And we're also trying to understand whether giving them in combinations will improve the outcomes and allow patients to discontinue treatment just as they do with chemotherapy, and that's our business on a daily basis right now on the clinical trial front.
And with that, I will conclude.
